Rajagopal Sunder, MD
Psychiatry · Villa Park, CANPI 1972572824
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.9% of the total across 7 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Alkermes, Inc. at 36.2% of the total. Reporting peaked in 2023 at $221 and has fallen 78.1% since, to $48 in 2025.
Across 7 payments — averaging $48.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$122
- Amgen$122
- Neuronetics, Inc.$31
- AbbVie$24
- Otsuka America Pharmaceutical, Inc.$24
- Hikma Pharmaceuticals USA$14
Across 17 payments — averaging $1409.95 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eisai Inc.$21K
- AbbVie$2K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$1K
What the payments were for
- Food & beverage$32396%
- Education$144%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 2 | $122 |
| Amgen | 1 | $122 |
| Neuronetics, Inc. | 1 | $31 |
| AbbVie | 1 | $24 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| Hikma Pharmaceuticals USA | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EVENITY$122
How this compares
$337 in reported general payments places this provider in the 60th percentile of 4,954 psychiatry providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Duloxetine Hcl | 15 | $359 |
| Bupropion XlBupropion Hcl | 28 | $342 |
| Memantine Hcl | 12 | $275 |
| Propranolol Hcl | 13 | $154 |
| Mirtazapine | 13 | $145 |
| Quetiapine Fumarate | 22 | $134 |
| Hydroxyzine Hcl | 12 | $123 |
| Trazodone Hcl | 17 | $112 |
| Buspirone Hcl | 22 | $110 |
| Fluoxetine Hcl | 16 | $95 |
| Escitalopram Oxalate | 14 | $76 |
| Sertraline Hcl | 15 | $70 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Villa Park
- Gustavo AlvaOrange$5.8M
- John KooSan Francisco$3M
- Jason KelloggIrvine$2.7M
- Jonathan MeyerSan Diego$2.3M
- Charles Tuan-Tu NguyenIrvine$2.1M
- Manoj WaikarLos Gatos$1.9M
- Gerald MaguireSan Juan Capistraco$1.8M
- Salima BrillmanSunnyvale$1.4M
- Bibi DasStanford$1.4M
- Konstantinos TripodisBurbank$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.